Clinical trial
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects With Irritable Bowel Syndrome Experiencing Abdominal Pain
NCT04043455 is registered in ClinicalTrials.gov with Arena Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects With Irritable Bowel Syndrome Experiencing Abdominal Pain
- Lead sponsor
- Arena Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 24, 2019
- Completion date
- April 29, 2021
- Enrollment
- 273 (actual)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.